Clinical trials · Tennessee
Neuroblastoma clinical trials in Tennessee
We’re tracking 12 recruiting neuroblastoma studies with a site in Tennessee — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Tennessee
- NCT01587300Recruiting
Study of high-risk neuroblastoma biology using tumor and blood samples
This study looks at how high-risk neuroblastoma grows and behaves by collecting samples from your child and checking disease markers. It may help researchers understand what biology is driving the cancer and guide future treatments.
Memphis, TennesseeAges 1 month–99 years - NCT06465199RecruitingPhase 1/Phase 2
Eflornithine and AMXT 1501 for Advanced Childhood Cancers
This trial tests a combination of two drugs (eflornithine and AMXT 1501) for children and young adults with certain types of cancer that have relapsed or not responded to standard treatment, or for a specific brain tumor (DIPG) at diagnosis. The goal is to see if this drug pair is safe and effective.
Nashville, TennesseeAges Up to 26 years - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Knoxville, TennesseeAges Up to 30 years - NCT07085338RecruitingPhase 2
N-803 with chemoimmunotherapy for relapsed neuroblastoma
This trial tests adding a new drug called N-803 to a standard chemo-immunotherapy combination for children and young adults with high-risk neuroblastoma that has come back or not responded to previous treatments. The goal is to see if this combination works better at fighting the cancer.
Memphis, TennesseeAges Up to 30 years - NCT03050268Recruiting
Study of childhood cancer risk in families
This study looks at inherited (family) risk for childhood cancers, including families with early cancers or known cancer risk conditions. It may help researchers understand why some children get cancer and improve future risk detection and care.
Memphis, TennesseeAges Any age - NCT03126916RecruitingPhase 3
Testing added therapy for high-risk neuroblastoma in children
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Knoxville, TennesseeAges 12 months–30 years - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Memphis, TennesseeAges 1–30 - NCT06450041RecruitingPhase 2
STING trial for high-risk neuroblastoma
This trial tests a combination of chemotherapy (temozolomide and irinotecan), natural killer cells (NK cells), and an antibody therapy (GD2 mAb) to see if it can help children and young adults with high-risk neuroblastoma that has not responded to treatment or has come back.
Memphis, TennesseeAges 1–31 - NCT06540963RecruitingPhase 2
Tipifarnib and naxitamab for relapsed or refractory neuroblastoma
This trial tests a combination of two drugs (tipifarnib and naxitamab) for children and young adults with neuroblastoma that has come back or hasn't responded to standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
Nashville, TennesseeAges 1–21 - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Memphis, TennesseeAges 1–30 - NCT04897321RecruitingPhase 1
CAR T therapy for children with B7-H3 solid tumors
This early-phase study tests a lab-made immune therapy (CAR T cells) made from your own cells to treat children’s solid tumors that have a specific marker called B7-H3. It is designed for kids whose cancer has come back or did not respond to standard treatment, aiming to shrink tumors and keep the therapy safe.
Memphis, TennesseeAges Up to 21 years - NCT06541262RecruitingPhase 1/Phase 2
Silmitasertib plus chemo for relapsed solid tumors
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Nashville, TennesseeAges Up to 30 years
Neuroblastoma trials by city in Tennessee
Where these studies are running in Tennessee
Institutions with a site for the recruiting neuroblastoma studies listed above.
- St. Jude Children's Research Hospital · 9 studies
- Vanderbilt University Medical Center · 5 studies
- East Tennessee Children's Hospital · 2 studies
- TriStar Centennial Medical Center · 2 studies
What taking part in a neuroblastoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Neuroblastoma trials in other states
Common questions
- Are there neuroblastoma clinical trials in Tennessee?
- Yes. We're currently tracking 12 recruiting neuroblastoma studies with a site in Tennessee, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a neuroblastoma study in Tennessee?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Tennessee to take part?
- Not necessarily. These studies have a site in Tennessee, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a neuroblastoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New neuroblastoma studies open in Tennessee regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.